Moreover, downregulation of Nogo-A led to alleviation of the cognitive impairment and microvascular dysfunction as well as the inhibition of the expression of S1PR2 and the RhoA/ROCK signaling pathway [46]. This evidence concerns the gene S1PR2 and Cognitive impairment.